Patel Seema, Panda Suryakanta
Affiliated to Better Process Control School, Department of Food Science and Technology, University of California, Davis, CA, USA.
Computer Technology Resources, Irvine, CA, USA.
3 Biotech. 2014 Feb;4(1):13-20. doi: 10.1007/s13205-013-0124-6. Epub 2013 Mar 7.
Mistletoes are a group of obligate plant semi-parasites in the order Santalales. These clumps of plants growing on a wide range of host plants have been traditionally regarded as medicinal repositories. However, current scientific discoveries have validated their health potentials like never before. Their extracts containing alkaloids, viscotoxins, lectins, and polysaccharides have been evidenced to possess a myriad biological potentials including cancer inhibition. Mistletoes have emerged as promising alternative therapy against colon, oral, lung, and pancreas cancers. The plant extracts bolster immunity, delay tumour initiation and progression, kill malignant tumours, stabilize DNA, alleviate side effects of chemotherapeutics, improve the lifespan, and coping ability of cancer patients and survivors. A range of proprietary formulations viz. Iscador, Eurixor, Helixor, Lektinol, Isorel, Iscucin, Abnoba-viscum and recombinant lectin ML-1 are already being commercialized. This review presents an informative account on the recent developments in mistletoe-mediated cancer management. The underlying mechanisms, possibilities and limitations in cancer therapeutic development are outlined for kindling both researcher and public interest.
槲寄生是檀香目一类专性植物半寄生虫。这些生长在多种寄主植物上的丛生植物传统上被视为药用植物库。然而，当前的科学发现前所未有地证实了它们的健康潜力。已证明其含有生物碱、槲寄生毒素、凝集素和多糖的提取物具有包括抑制癌症在内的多种生物学潜力。槲寄生已成为对抗结肠癌、口腔癌、肺癌和胰腺癌的有前景的替代疗法。植物提取物可增强免疫力、延缓肿瘤起始和进展、杀死恶性肿瘤、稳定DNA、减轻化疗副作用、提高癌症患者和幸存者的寿命及应对能力。一系列专利制剂，即益可多、优利克索、喜疗妥、来替诺、伊索雷、伊斯库辛、阿波那槲寄生和重组凝集素ML-１已实现商业化。本综述介绍了槲寄生介导的癌症治疗的最新进展。概述了癌症治疗开发中的潜在机制、可能性和局限性，以激发研究人员和公众的兴趣。
